<< Back
Questcor Announces the Addition of Craig Chambliss as Vice President of Sales & Marketing

UNION CITY, Calif., May 02, 2005 (BUSINESS WIRE) -- Questcor Pharmaceuticals, Inc. (AMEX:QSC), a specialty pharmaceutical company, announced today that Craig Chambliss has joined the company as Vice President of Sales & Marketing.

"We are excited to have Craig join Questcor. His experience and abilities will be a welcome addition to the Questcor team. Craig's specialty pharmaceutical background, experience with Central Nervous System products, and skills in sales, marketing, and management are an ideal fit for Questcor," explained Jim Fares, Questcor's President and CEO.

Mr. Chambliss has 14 years of experience in the specialty pharmaceutical and drug delivery industries. Mr. Chambliss joins Questcor from Xcel Pharmaceuticals where he was Vice President of Sales & Marketing. He joined Xcel, a private start up company, in 2001. He was a key contributor to Xcel's rapid sales growth, product acquisitions, and development programs. Previously, Mr. Chambliss was the Director of Business Development for Elan Corporation, where he was responsible for developing and optimizing Elan's Central Nervous System (CNS) product portfolio. Before joining Elan in early 2000, Mr. Chambliss worked for Ther-Rx Corporation as Director of Marketing. Prior to Ther-Rx, Craig spent five years with Alza Pharmaceuticals in various sales and marketing management roles and began his career in sales at Bristol-Myers Squibb. Mr. Chambliss received his bachelor's degrees from Southwest Missouri State University in Finance and Accounting.

Mr. Chambliss will be responsible for Questcor's sales and marketing efforts and ensuring the commercial success of the company's new CNS focus.

About Questcor

Questcor Pharmaceuticals, Inc.(R) (AMEX:QSC) is a specialty pharmaceutical company that develops, acquires, markets and sells brand name prescription drugs for neurological and other uses through a U.S. direct sales force and international distributors. Questcor currently markets four products in the U.S.: H.P. Acthar(R) Gel (repository corticotropin injection), an injectable drug that is commonly used for certain neurological conditions; Nascobal(R), the only prescription nasal gel formulation of Cyanocobalamin USP (Vitamin B12), that is approved for patients with B12 deficiency caused by malabsorptive disorders resulting from structural or functional damage, such as bariatric surgery, Crohn's disease and certain neurological conditions; Ethamolin(R) (Ethanolamine Oleate), an injectable drug used to treat enlarged weakened blood vessels at the entrance to the stomach that have recently bled, known as esophageal varices; and Glofil-125(R), which is an injectable agent that assesses how well the kidney is working by measuring glomerular filtration rate, or kidney function.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties. Such statements are subject to certain factors, which may cause Questcor's results to differ from those reported herein. Factors that may cause such differences include, but are not limited to, Questcor's ability to accurately forecast and create the demand for each of its products, the gross margins achieved from the sale of those products, Questcor's ability to enforce its exchange policy, the accuracy of the prescription data purchased from independent third parties by Questcor, the sell through by Questcor's distributors, the inventories carried by Questcor's distributors, and the expenses and other cash needs for the upcoming periods, Questcor's ability to obtain finished goods from its sole source contract manufacturers on a timely basis if at all, Questcor's need for additional funding, uncertainties regarding Questcor's intellectual property and other research, development, marketing and regulatory risks, and, to the ability of Questcor to implement its strategy and acquire products and, if acquired, to market them successfully as well as the risks discussed in Questcor's report on Form 10-K for the calendar year ended December 31, 2004 and other documents filed with the Securities and Exchange Commission. The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.

Questcor undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE: Questcor Pharmaceuticals, Inc.

Questcor Pharmaceuticals, Inc.
James L. Fares, 510-400-0700
Could not find file '\\pro.dianum.io\irwebpro\content3\IRXMLDATA\89\89528\Disclaimers.xml'.